Bolt Biotherapeutics (BOLT) to Release Earnings on Thursday

Bolt Biotherapeutics (NASDAQ:BOLT) is anticipated to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Bolt Biotherapeutics to post earnings of ($0.38) per share and revenue of $0.79 million for the quarter.

Bolt Biotherapeutics Trading Down 0.9 %

Bolt Biotherapeutics stock opened at $0.41 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The business’s 50-day simple moving average is $0.49 and its 200-day simple moving average is $0.57. The firm has a market capitalization of $15.70 million, a PE ratio of -0.24 and a beta of 0.94. Bolt Biotherapeutics has a 52 week low of $0.39 and a 52 week high of $1.56.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.